On December 2, 2024, William Carson, a Director at Annexon Inc (ANNX, Financial), purchased 3,200 shares of the company. Following this transaction, the insider now owns a total of 25,600 shares. The purchase was documented in a SEC Filing.
Annexon Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. The company's approach targets the classical complement pathway, which is a key driver of inflammation and tissue damage in a range of autoimmune and neurodegenerative diseases.
The insider's recent acquisition is part of a broader trend observed over the past year, where William Carson has purchased a total of 25,600 shares and has not sold any shares. This activity is set against a backdrop of 9 insider buys and 17 insider sells within the company over the same period.
Shares of Annexon Inc were trading at $5.33 each on the day of the insider's purchase, resulting in a market cap of $550.022 million for the company.
For investors, insider buying can be a signal of confidence in the company's future prospects. However, it is important to consider this information alongside other financial metrics such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow to make informed investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
